Literature DB >> 17163100

Hepatic resection in the treatment of hilar cholangiocarcinoma.

David M Nagorney1, Michael L Kendrick.   

Abstract

HC is an uncommon--although readily recognizable-clinical entity. Although current hepatobiliary imaging has improved, accurate staging of HC preoperatively is difficult. In patients who have potentially resectable HC, careful preoperative preparation with biliary drainage, portal vein embolization, or both is indicated because major hepatic resection has become an essential component of surgical treatment, and these interventions may reduce perioperative risks. Currently, lobar or extended lobar hepatic and bile duct resection, regional lymphadenectomy, and Roux-en-Y hepaticojejunostomy are the treatments of choice for HC. Whether major vascular resection coupled with these procedures or hepatic transplantation in selected patients will improve overall survival is unknown. Finally, current outcomes dictate investigation of effective adjuvant therapy.

Entities:  

Mesh:

Year:  2006        PMID: 17163100     DOI: 10.1016/j.yasu.2006.05.009

Source DB:  PubMed          Journal:  Adv Surg        ISSN: 0065-3411


  19 in total

Review 1.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

2.  Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

Review 3.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

4.  The expression of S100A4 protein in human intrahepatic cholangiocarcinoma: clinicopathologic significance and prognostic value.

Authors:  Xiangguo Tian; Qizhi Wang; Yan Li; Jinhua Hu; Lei Wu; Qian Ding; Chunqing Zhang
Journal:  Pathol Oncol Res       Date:  2014-07-02       Impact factor: 3.201

5.  Cholangiocarcinoma treatment.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 6.  [Diagnostics and treatment of cholangiocellular carcinoma].

Authors:  L Zender; N P Malek
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 7.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 8.  Current diagnostic and management options in perihilar cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Digestion       Date:  2014-05-22       Impact factor: 3.216

Review 9.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

10.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.